Brokerages Set CG Oncology, Inc. (NASDAQ:CGON) PT at $63.88

Shares of CG Oncology, Inc. (NASDAQ:CGON) have earned a consensus rating of “Buy” from the ten research firms that are presently covering the stock, MarketBeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $63.88.

Several equities analysts recently weighed in on CGON shares. Morgan Stanley reaffirmed an “overweight” rating and set a $55.00 price objective on shares of CG Oncology in a research report on Friday, March 7th. HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a research report on Friday, January 10th. TD Cowen assumed coverage on shares of CG Oncology in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $66.00 price target on shares of CG Oncology in a research report on Friday, December 6th.

Insider Buying and Selling

In related news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $29.66, for a total transaction of $29,660.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Institutional Investors Weigh In On CG Oncology

Institutional investors have recently bought and sold shares of the business. State Street Corp boosted its stake in CG Oncology by 73.0% during the third quarter. State Street Corp now owns 1,700,653 shares of the company’s stock worth $64,166,000 after buying an additional 717,722 shares in the last quarter. Ally Bridge Group NY LLC boosted its stake in CG Oncology by 50.5% during the third quarter. Ally Bridge Group NY LLC now owns 263,266 shares of the company’s stock worth $9,933,000 after buying an additional 88,390 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in CG Oncology by 114.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company’s stock worth $14,325,000 after buying an additional 202,262 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in CG Oncology by 876.9% during the third quarter. BNP Paribas Financial Markets now owns 26,660 shares of the company’s stock worth $1,006,000 after buying an additional 23,931 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in CG Oncology by 59.1% during the third quarter. JPMorgan Chase & Co. now owns 31,071 shares of the company’s stock worth $1,172,000 after buying an additional 11,542 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Stock Up 2.0 %

Shares of CGON opened at $28.03 on Friday. The firm’s 50 day moving average price is $28.20 and its 200 day moving average price is $32.30. CG Oncology has a twelve month low of $23.91 and a twelve month high of $46.99.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.